Denali Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.08M Sell
13,287
-306
-2% -$45.9K 0.21% 125
2026
Q1
$2.08M Sell
13,593
-5
-0% -$766 0.23% 114
2025
Q4
$1.87M Buy
13,598
+39
+0.3% +$5.11K 0.21% 113
2025
Q3
$1.74M Sell
13,559
-8,254
-38% -$1.01M 0.2% 123
2025
Q2
$2.64M Sell
21,813
-123
-0.6% -$13.9K 0.27% 100
2025
Q1
$2.45M Sell
21,936
-176
-0.8% -$18.7K 0.28% 107
2024
Q4
$2.15M Buy
22,112
+417
+2% +$44.5K 0.23% 128
2024
Q3
$2.5M Buy
+21,695
New +$2.46M 0.27% 111

Other funds holding NVS

Denali Advisors's NVS Position: Q2 2026 in Review

Denali Advisors reduced its Novartis (NVS) stake by 2.3% in Q2 2026, selling an estimated $45.9K and leaving 13,287 shares worth $2.08M. The position accounts for 0.21% of the portfolio, ranked #125.

Denali Advisors first reported a position in NVS in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.64M in Q2 2025. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Denali Advisors held 13,287 shares of Novartis worth $2.08M as of Q2 2026.
  • Denali Advisors sold 306 Novartis shares in Q2 2026, an estimated $45.9K.
  • Novartis made up 0.21% of Denali Advisors's portfolio in Q2 2026, its #125 holding.
  • Denali Advisors first reported a position in Novartis in Q3 2024 and has held it in 8 quarters since.
  • Denali Advisors's Novartis position peaked at $2.64M in Q2 2025.
  • 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Denali Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.